Zobrazeno 1 - 10
of 246
pro vyhledávání: '"Koichi, Amano"'
Autor:
Yoshiya Tanaka, Mitsumasa Kishimoto, Koshiro Sonomoto, Koichi Amano, Masayoshi Harigai, Alina Onofrei, Jacqueline O’Brien, Zachary Margolin, Christine Barr, Yasushi Mizuno, Ekta Agarwal, Naonobu Sugiyama, Hisashi Yamanaka
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1237-1253 (2024)
Abstract Introduction The evolution of disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA) has improved patient prognosis. However, more real-world safety/effectiveness data comparing methotrexate (MTX), tofa
Externí odkaz:
https://doaj.org/article/bd4e692904d347f48204599691f8f2c3
Autor:
Miku Yoshinari, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Yoshihiro Arimura, Koichi Amano, Yukio Yuzawa, Ken-Ei Sada, Tatsuya Atsumi, Hiroaki Dobashi, Hitoshi Hasegawa, Masayoshi Harigai, Seiichi Matsuo, Hirofumi Makino, Akihiro Ishizu
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-9 (2022)
Abstract Background Neutrophil extracellular traps (NETs) are critically involved in microscopic polyangiitis (MPA) pathogenesis, and some patients with MPA possess anti-NET antibody (ANETA). Anti-myosin light chain 6 (MYL6) antibody is an ANETA that
Externí odkaz:
https://doaj.org/article/d4340aa3fa924e148ce2b22195564db0
Autor:
Yuko Kaneko, Hideto Kameda, Yoshiya Tanaka, Satoshi Kubo, Koichi Amano, Shingo Nakayamada, Yusuke Miyazaki, Kiyoshi Matsui, Yoshino Inoue, Kunihiro Yamaoka, Takehisa Ogura
Publikováno v:
RMD Open, Vol 9, Iss 2 (2023)
Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirhe
Externí odkaz:
https://doaj.org/article/4267bc8365004aff9bd271fa347e299f
Publikováno v:
BJPsych Open, Vol 9 (2023)
Background Hypersalivation is a major side-effect of clozapine in patients with treatment-resistant schizophrenia. Aims We investigated the efficacy of topical anticholinergic formulation sofpironium bromide gel for improving hypersalivation in pati
Externí odkaz:
https://doaj.org/article/3cbd1569f363428aab6eda6c1e616752
Autor:
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki, for the TOF-ABT Study Group
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA). M
Externí odkaz:
https://doaj.org/article/8072e3ec640d40be86ca5bbb0e68cc83
Autor:
Jun Ishizaki, Ayako Takemori, Kenta Horie, Daisuke Hiraoka, Koichiro Suemori, Takuya Matsumoto, Ken-ei Sada, Koichi Amano, Masayoshi Harigai, Yoshihiro Arimura, Hirofumi Makino, Katsuto Takenaka, Nobuaki Takemori, Hitoshi Hasegawa, for the Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-15 (2021)
Abstract Background We previously identified tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker of disease activity that distinguished mildly or highly active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) from re
Externí odkaz:
https://doaj.org/article/a72fdcfdd8d64c048ec2f65e4f092f5d
Autor:
Haruki Watanabe, Ken-ei Sada, Masayoshi Harigai, Koichi Amano, Hiroaki Dobashi, Yoshinari Takasaki, Shouichi Fujimoto, Tatsuya Atsumi, Kunihiro Yamagata, Sakae Homma, Yoshihiro Arimura, Hirofumi Makino, Research Committee of Intractable Vasculitis Syndrome (JPVAS), Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract A novel patient cluster in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may be identified in Japan. We performed multiple correspondence and cluster analysis regarding 427 clinically diagnosed AAV patients excluding
Externí odkaz:
https://doaj.org/article/47228f3b83d241069b3bd203537b1d6a
Autor:
Ken-Ei Sada, Keiji Ohashi, Yosuke Asano, Keigo Hayashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Shouichi Fujimoto, Yoshinari Takasaki, Kunihiro Yamagata, Shogo Banno, Hiroaki Dobashi, Koichi Amano, Masayoshi Harigai, Yoshihiro Arimura, Hirofumi Makino, the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-8 (2020)
Abstract Background It is not elucidated that there is treatment-related damage in elderly patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Methods Elderly (≥ 75 years of age) patients were enrolled from two n
Externí odkaz:
https://doaj.org/article/15a880d6233d4fa89271a52463c0361e
Autor:
Waka Yokoyama-Kokuryo, Hayato Yamazaki, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Tsuneo Kondo, Seiji Nakamura, Ryoko Sakai, Fumio Hirano, Toshihiro Nanki, Ryuji Koike, Masayoshi Harigai
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-8 (2020)
Abstract Background Abatacept (ABA) is a biological disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA). The aim of this study was to identify molecules that are associated with therapeutic responses to ABA in patients with RA
Externí odkaz:
https://doaj.org/article/9a125c5b757142cdaea09bf9238f9372
Autor:
Kyota Hashimoto, Ryota Sakai, Akiko Shibata, Yusuke Okada, Syoichi Yoshinaga, Takahiko Kurasawa, Tsuneo Kondo, Koichi Amano
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
Takayasu arteritis (TAK) is a rare primary systemic inflammatory vasculopathy. It is classified as a large-vessel vasculitis and is known to cause inflammatory aneurysms and vascular stenosis. Vascular Ehlers–Danlos syndrome (vEDS) is an autosomal
Externí odkaz:
https://doaj.org/article/6a3124ebceeb4e5e8d699a2afe299e9a